Skip to contentA
Acro Biomedical Co., Ltd.
A
ACBMAcro Biomedical Co., Ltd. Q2 2023 · 10-Q
Revenue$0.00$0.00— vs Q2 2022 Net Income-$3.20M-$3.20MN/M vs Q2 2022 EPS Diluted-$0.05-$0.05no prior Q2 2022 on file The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
Operating Cash Flowderived$2,250N/M ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end